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Abstract
Excessive blood vessel formation in the eye is implicated in wet age-related macular degeneration, 
proliferative diabetic retinopathy, neovascular glaucoma and retinopathy of prematurity, which are 
major causes of blindness. Small molecule antiangiogenic drugs are strongly needed to 
supplement existing biologics. Homoisoflavonoids have been previously shown to have potent 
anti-proliferative activities in endothelial cells over other cell types. Moreover, they demonstrated 
a strong antiangiogenic potential in vitro and in vivo in animal models of ocular 
neovascularization. Here, we tested the antiangiogenic activity of a group of naturally occurring 
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homoisoflavonoids isolated from the family Hyacinthaceae and related synthetic compounds, 
chosen for synthesis based on structure activity relationship observations. Several compounds 
showed interesting anti-proliferative and antiangiogenic activities in vitro on retinal microvascular 
endothelial cells, a disease-relevant cell type, with the synthetic chromane, 46, showing the best 
activity (GI50 of 2.3 × 10−4 µM).
Graphical Abstract
Abnormal formation of new blood vessels in the eye is associated with blindness in many 
ocular diseases such as retinopathy of prematurity (ROP) affecting children, proliferative 
diabetic retinopathy (PDR), the wet form of age-related macular degeneration (AMD) and 
neovascular glaucoma affecting adults, and elderly people, respectively.1 The newly formed 
vasculature is fragile and leaky causing hemorrhage and accumulation of fluids in the retina. 
If left untreated, the resulting edema and fibrotic scarring can lead to irreversible vision loss.
2
 The current pharmacotherapeutic mainstays for these diseases are biologics targeting the 
vascular endothelial growth factor (VEGF) such as bevacizumab, ranibizumab, and 
aflibercept.3 Despite being successful in suppressing disease progression, these large 
molecule therapies are associated with some undesirable ocular and systemic side effects as 
well as the time consuming regular visits to hospitals required for the intravitreal injections.
4,5
 Moreover, resistance is a problem: about 30% of wet AMD patients are resistant to these 
biologics.6 Currently, there is no FDA approved small molecule for the treatment of ocular 
neovascularization. Therefore, there is an unmet need to develop novel and specific anti-
angiogenic small molecule therapies to complement and combine with existing drugs for 
ROP, PDR, and wet AMD.
Natural products continue to provide appealing lead compounds for treatment of diseases.7 
Naturally occurring homoisoflavonoids are reported to have diverse biological activities 
including antioxidant, anti-inflammatory and antiangiogenic activities.8 The Hyacinthaceae 
is one of the families rich in homoisoflavonoids distributed in different parts of the plants. 
The Hyacinthaceae (sensu APGII) consists of approximately 900 species, in about 70 
genera. The family can be divided into four subfamilies, the widespread Hyacinthoideae, 
Urgineoideae and Ornithogaloideae and the small sub-family Oziroëoideae which is 
restricted to South America. For the most part, the compounds found are sub-family 
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restricted. Homoisoflavonoids and spirocyclic nortriterpenoids characterise the 
Hyacinthoideae, bufadienolides the Urgineoideae and cardenolides and steroidal glycosides 
the Ornithogaloideae. To date, no phytochemical investigations have been reported of the 
Oziroëoideae.9
Members of the Hyacinthoideae subfamily have a long tradition of being used by traditional 
healers to treat a wide range of complaints. Phytochemical investigations of the genus 
Eucomis L’Hér.,10 Ledebouria revoluta (L.F.) Jessop,11 Ledebouria ovatifolia (Baker) 
Jessop,12 Merwilla plumbea (Lindl.) Speta13 all widely used in African traditional medicine, 
have been reported.
Previously, a homoisoflavanone, cremastranone, isolated from the orchid Cremastra 
appendiculata (D.Don) Makino, was shown to have antiangiogenic activity in the ocular 
context, but unfortunately, the configuration at C-3 was not reported.14–16 This compound 
was also previously isolated from the Hyacinthoideae genera Muscari Mill.,17 and Merwilla 
Speta.13 More recently, a synthetic racemate of this compound showed strong antiangiogenic 
activity against human retinal microvascular endothelial cells (HRECs), with lesser effects 
on non-endothelial cell types.18 A synthetic regioisomer of cremastranone (SH-11052) also 
had antiangiogenic activities in vitro.19 Subsequently, our SAR campaign identified a 
promising synthetic analogue of cremastranone, named SH-11037, with more potent and 
selective antiproliferative effects on HRECs compared to endothelial cells of macrovascular 
origin.20 Moreover, SH-11037 demonstrated strong antiangiogenic potential in vivo in 
animal models of ROP20 and choroidal neovascularization.21 We have also isolated known 
and novel homoisoflavonoids from Massonia Houtt. species, some of which showed 
selective antiproliferative effects on HRECs.22 Given the selective and potent antiangiogenic 
activity of cremastranone and derivatives, the search for further antiangiogenic 
homoisoflavonoids is warranted. In parallel with our medicinal chemistry approach,20 we 
have here further explored natural-source and related synthetic homoisoflavonoids as 
antiangiogenic agents.
Homoisoflavonoids and related compounds isolated from seven species of Hyacinthaceae 
have been investigated in this study for antiangiogenic activity. The isolation and structure 
determination of compounds from Ledebouria socialis (Baker) Jessop (1, 2), Ledebouria 
ovatifolia (Baker) Jessop (3-14), Rhodocodon campanulatus Knirsch (25, 26), Mart-Azorín 
and Wetschnig, Rhodocodon aff. intermedius Knirsch, Mart-Azorín and Wetschnig (27-29), 
have been reported by us previously and compounds from these sources were screened as 
part of this work.23,24 In addition, Chionodoxa luciliae Boiss, Eucomis autumnalis (Mill.) 
Chitt. and Eucomis bicolor Baker were re-investigated to provide material for screening and 
a previously unreported homoisoflavonoid, 35, along with previously reported ones were 
isolated, some for the first time from these sources. These species were chosen for re-
extraction due to large amounts of bulb material being available from a commercial supplier 
enabling us to isolate large amounts of compounds for screening purposes.
In addition, based on our cell-based structure-activity observations, a number of known (44, 
47, 48) and previously undescribed homoisoflavonoids (42, 43, 45, 46, 49 and 50) were 
synthesized and investigated for antiangiogenic activity, including the enantioselective 
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synthesis of compound 45 with the 3R configuration. Compound 46, a previously 
undescribed compound with a chromane skeleton, showed significantly greater activity than 
the related chromanones (45 and 47).
RESULTS AND DISCUSSION
The EtOH extract of the bulbs of Chionodoxa luciliae Boiss yielded compound 16, para-
hydroxybenzaldehyde, and homoisoflavonoids 15, 17 and 21-24. Compound 17 was 
acetylated and yielded the 7-acetate (19) and 3,7-diacetate (20). Compound 16 is likely to be 
a degradation product of compound 21. All compounds have been reported previously from 
several sources9,25 but this is the first report of the isolation of compounds 17, 22 and 23 
from a Chionodoxa species. Structures were determined using NMR techniques and were 
confirmed by comparison against literature data; the configurations at C-3 were confirmed 
using circular dichroism spectroscopy and optical rotation measurements.
The MeOH and butanol extracts of the bulbs of Eucomis autumnalis yielded compounds 22 
and 30-39 and the EtOH extract of the bulbs of E. bicolor yielded compounds 40 and 41. 
Compounds 31 and 32 have been isolated previously from both E. autumnalis and E. bicolor,
26
 compound 36 from E. autumnalis,27,28,29 compounds 30, 40 and 41 from E. bicolor,
27,30,31
 compound 33 from E. montana,32 compound 38 from Muscari armeniacum,17 
compound 39 from Scilla persica33 and compound 37 from Ledebouria ovatifolia.23
Compound 35, 3R-(4ʹ-hydroxybenzyl)-6,8-dihydroxy-5,7-dimethoxy-4-chromanone, is a 
homoisoflavonoid that has not been reported previously with a fully substituted ring A. 
HRMS showed a protonated molecular ion at m/z 347.11254 corresponding to a molecular 
formula of C18H18O7. Characteristic peaks at δH 4.37 (H-2α, dd, 11.4, 4.1 Hz), δH 4.20 
(H-2β, dd, 11.4, 7.2 Hz), 2.79 (H-3, m), δH 3.17 (H-9A, dd, 14.0, 4.4 Hz) and δH 2.70 
(H-9B, dd, 14.0, 10.6 Hz) were indicative of a 3-benzyl-4-chromanone structure and 
resonances at δH 6.79 (2H, 3ʹ,5ʹ, 8.1 Hz) and δH 7.11 (2H, 2ʹ and 6ʹ, 8.1 Hz) showed that 
the B ring was para-disubstituted. The two H-2 and two H-9 resonances showed correlations 
with the C-4 keto group carbon resonance at δC 192.0. Two methoxy group proton 
resonances and three exchangeable hydroxy group proton resonances (δH 5.59, 6-OH; δH 
5.39, 8-OH and δH 4.74, 4ʹ-OH) could be assigned from correlations seen in the HMBC 
spectrum (Figure 1). A specific rotation of −55.6 and negative Cotton effect at 290 nm 
indicated a 3R-configuration.11 Homoisoflavonoids with a fully substituted ring A are rare 
with only two similar compounds being reported previously: (4ʹ-hydroxybenzyl)-5,6-
dihydroxy-7,8-dimethoxy-4-chromanone, from Bellevalia eigii 34 and (4ʹ-hydroxy)-5,8-
dihydroxy-6,7-dimethoxy-4-chromanone, from Muscari comosum.35
Previous work on synthetic analogues of cremastranone demonstrated that much potential 
remained for the improvement of activity. Previously, 3-benzyl analogues had been 
synthesised as racemic mixtures and we wished to investigate the possibility of synthesising 
a single enantiomer via selective hydrogenation of the 3,9-double bond of a 3-benzylidene 
analogue. In addition, the effect of producing the chromane derivative of 5,6,7-trimethoxy-3-
(3ʹ-hydroxy-4ʹ-methoxybenzylidene)-4-chromanone was of interest. Homoisoflavonoids 42 
to 49 were synthesised following known methods36 (Schemes 1 and 2). An iridium catalyst, 
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the (S)-4-tert-butyl-2-[2-(diphenylphosphino)phenyl]-2-oxazoline complex, also known as 
iridium–phosphino-oxazoline or phox, used to hydrogenate compound 44 to form 45, was 
synthesised using known methodology37 and is shown in Scheme 2. Chalcone 50 was 
synthesised via a Claisen-Schmidt condensation, using known methods.38
Syntheses of compounds 44, 47 and 48 have been reported 20,39 while the synthesis of 
compounds 42, 43, 45, 46, 49 and 50 has not been reported before. Compounds 42 and 43 
were both synthesised in low yield (3 and 3.5% respectively). The first two steps proceeded 
well, with the low yield being a result of poor reaction completion in step three and 
extensive chromatography to produce the pure product. The structures were confirmed by 
high resolution mass spectrometry and NMR analysis.
Compound 44 was used as a starting point for our investigation into the asymmetric 
hydrogenation of the 3,9-double bond in the benzylidene-type homoisoflavonoids using the 
iridium catalyst (Scheme 2) for the hydrogenation. The reaction proceeded quantitatively to 
give compound 45.
A systematic conformational search of 3R- and 3S-isomers of 5,6,7-trimethoxy-(3ʹ-
hydroxy-4ʹ-methoxybenzyl)-4-chromanone was performed via molecular mechanics force 
field calculation (MMFF) built in the software Spartan’16. Conformers under 3.0 kJ/mol 
relative energy cut-off were selected and optimised using Density Functional Theory (DFT) 
calculations at B3LYP/6–31 G + (d,p) level built into Gaussian09. Once optimised, their 
ECD spectra were simulated using Time Dependant Density Functional Theory (TDDFT) at 
the B3LYP/6–31 + G (d,p) level. A polarisable continuum model (IEFPCM) was applied 
during the TDDFT calculation to simulate the presence of acetonitrile, which was the 
solvent used in the experimental ECD. The ECD spectra obtained for each conformer were 
Boltzmann weighted and compared to the experimental ECD spectrum of 45.40 The 6–31 + 
G(d,p) basis set was applied as it provides a fine balance between accuracy and 
computational time needed. In addition, it has been applied in the past by our group with 
satisfactory results.41
The measured ECD spectrum of 45 showed a positive Cotton effect at λ (Δε) 326 (+1.3) 
and a negative Cotton effect at λ (Δε) 284 (−1.9), which is in accordance with the 
theoretical calculated spectrum for the 3R-enantiomer, indicating the 3R configuration for 
compound 45 (Supporting Information).42 For comparative purposes compound 44 was 
hydrogenated using Pd/C to give the racemic mixture, 46. This reaction resulted in the 
reduction of both the 3,9-double bond as well as the carbonyl group at C-4 as shown by the 
loss of the fully-substituted carbon resonance at δC 179.8 (C-4) and the new methylene 
resonance at δC 37.5 (C-4). Coupling could clearly be seen in the COSY spectrum between 
the resonance at δH 2.14 (1H, m, H-3) and the resonance at δH 2.53 (2H, dd, J = 4.1 and 7.4 
Hz, H-4). Compound 44 was then successfully hydrogenated using Wilkinson’s catalyst 
(tris(triphenylphosphine)rhodium(I) chloride) to give compound 47, the previously 
synthesised racemate.20 Compound 48 was synthesised to determine whether the presence of 
a 5-OH group was significant for activity. Many natural homoisoflavonoids have a hydroxyl 
group at C-5. The selective demethylation was confirmed by the appearance of a sharp 
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singlet at δH 12.45, due to the proton of a H-bonded hydroxyl group at C-5. In addition, 
three methoxy groups were noted instead of four.
Compound 49 was synthesised from 3,4,5-trimethoxyphenol and 4-chloro-3-
hydroxybenzaldehyde and the expected product was formed. A HRESIMS value of m/z 
377.0786 [M + H]+ indicated a molecular formula of C19H17O6Cl. The structure of the 
product was confirmed by key 1H NMR resonances at δH 4.99 (2H, d, J = 1.8 Hz, H-2), 7.75 
(1H, bs, H-9), 6.16 (1H, s, H-8) and three methoxy group three-proton resonances at δH 3.75 
(3H, s), 3.82 (3H, s) and 3.91(3H, s). The B-ring resonances at δH 7.15 (1H, dd, J = 2.4 and 
8.6 Hz, H-2ʹ), 6.91 (1H, d, J = 2.4, H-6ʹ) and 6.83 (1H, d, J = 8.6, H-3ʹ) supported the 4ʹ, 
5ʹ-substitution pattern.
Compound 50, a chalcone, was synthesised from 3,4-dimethoxybenzaldehyde and 4ʹ-
ethoxy-2ʹ-hydroxy-3ʹ-methylacetophenone via a Claisen-Schmidt condensation. The 
HRESIMS gave a [M+H]+ ion at m/z 343.1545, giving a molecular formula of C20H22O5 for 
the compound. The chalcone structure was confirmed by a pair of doublets in the 1H NMR 
spectrum at δH 7.47 (1H, d, J = 15.2 Hz, H-2) and 7.84 (1H, d, J = 15.2 Hz, H-3) indicative 
of E geometry.
Antiproliferative activities of homoisoflavonoids
To find novel antiangiogenic homoisoflavonoids, compounds were tested for their 
antiproliferative activities on HRECs. To assess effects on other normal cell types, we tested 
compounds against primary macrovascular human umbilical vein endothelial cells 
(HUVECs; a non-target endothelial cell type) or the retinal pigment epithelial cell line, 
ARPE-19, a non-target ocular cell type. Ideal antiangiogenic candidates should have lesser 
effects on these non-target cell types than on HRECs. To further assess potential cytotoxic 
effects against ocular cell types, we also employed two ocular cancer cell lines, uveal 
melanoma 92–1 and retinoblastoma Y79. Again, ideal candidates for further investigation as 
antiangiogenic homoisoflavonoids should show lower activity against these other ocular cell 
lines derived from uveal melanocytes and photoreceptor precursors, respectively.
While many of the compounds lacked activity against the cell types, some compounds were 
reasonably potent and selective for the endothelial cell types (Tables 1 and 2; Figures 2–4). 
The results would suggest some structural features are significant in determining the activity 
of the homoisoflavonoid. Optimal activity was observed when the A-ring was either 5,6,7-
trisubstituted or 5,7-disubstituted. If only two substituents were present, at least one of them 
would need to be an acetyl rather than a hydroxy group. 3ʹ,4ʹ -Disubstitution in ring B 
produced the highest activity, in particular when combined with the presence of a 3/9 double 
bond. Homoisoflavonoids with the bulkier 3ʹ-acetyl group were more active than ones with 
the 3ʹ-hydroxyl group. The presence of a cyclobutane ring rendered the homoisoflavonoid 
inactive, regardless of the substituents on rings A and B. The importance of a 5,6,7-
trisubstituted A-ring was confirmed by the synthetic samples, with the trisubstituted 
compounds (44, 45, 46, 47, 48 and 49) showing better activity than the disubstituted 
compounds (42 and 43). Interestingly, the 3R-enantiomer (45) showed greater activity than 
the precursor with a double bond in the 3,9-position (44) as well as greater activity than the 
racemic mixture (47). This serves to emphasise the importance of being able to synthesise 
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these homoisoflavonoids enantioselectively. The complete reduction of both the 3,9-double 
bond and the carbonyl group at C-4 produced a highly active compound (46) (Table 2, GI50 
(HREC) of 2.3 × 10−4 μM, GI50 (ARPE-19) of 3.4 × 10−4 μM, and GI50 (92–1) of 52 μM). 
This significant increase in activity with the loss of the carbonyl group at C-4 has not been 
reported before, although this compound was synthesized simultaneously by the Seo lab 
(personal communication). Compound 49, with a 4ʹ-chloro-3ʹ-hydroxyphenylbenzylidene 
group at C-3 produced good activity with selectivity for HRECs (Table 2, GI50 (HREC) of 
0.11 μM, GI50 (92–1) of 3.6 μM), compared to that of compound 44 (Table 2, GI50 (HREC) 
of 2.2 μM, GI50 (92–1) of 8.2 μM). By way of comparison, cremastranone as reported was 
substantially less potent, but still selective (GI50 (HREC) of 0.22 μM, GI50 (HUVEC) of 
0.38 μM, GI50 (92–1) of 48 μM, GI50 (Y79) of 9.8 μM).20
In vitro antiangiogenic efficacy of the potent homoisoflavonoids
After identifying some of the most potent anti-proliferative compounds with some selectivity 
for HRECs – compounds 13, 27, 28, 45, 46, 48, and 50– we further investigated their 
potential in inhibiting the ability of HRECs to form tubes. Matrigel based tube formation is 
the gold-standard in vitro assay that recapitulates most of the physiological angiogenesis 
events such as cell proliferation, migration, and cell-cell adhesion, as endothelial cells form 
three dimensional tube-like structures.43 Interestingly, all three of the natural-source 
compounds (13, 27, and 28), inhibited the ability of HRECs to form tubes in a 
concentration-dependent manner (Figure 3). Three potent synthetic compounds, 48, 45, and 
50, were also effective (Figure 4), while the most potent antiproliferative compound, 46, 
maintained this low-dose efficacy in the tube formation assay (Figure 5).
CONCLUSIONS
A group of naturally occurring homoisoflavonoids isolated from the Hyacinthaceae as well 
as compounds synthesized have been tested for their antiangiogenic activities. The most 
potent compounds, 13, 28, 29, 42, 43, 45, 46, 48 and the chalcone 50, demonstrated selective 
antiproliferative activities on endothelial cells compared to non-endothelial cell types, with 
concentration-dependent antiangiogenic effects in vitro on HRECs, a disease-relevant cell 
type. Recently, intracellular target proteins for some other bioactive homoisoflavonoids have 
been identified: ferrochelatase as a target of cremastranone,44 soluble epoxide hydrolase as a 
target of SH-11037 (a synthetic Boc-Phe-derivatized homoisoflavonoid),45 and inosine 
monophosphate dehydrogenase 2 as a target of sappanone A.46 The relative effects of the 
natural products described here on each of these enzymes will be a valuable topic for future 
exploration. Our results will open the doors to the development of further synthetic 
analogues with higher potency and better antiangiogenic activities to treat blinding eye 
diseases caused by pathological neovascularization.
EXPERIMENTAL SECTION
General Experimental Procedures.
NMR spectra were recorded on a 500MHz Bruker AVANCE NMR instrument in either 
CDCl3 or CD3OD at room temperature. All chemical shifts (δ) are in ppm and referenced to 
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the relevant solvent references, 7.26 ppm (CDCl3) and 4.87 ppm (CD3OD) for 1H NMR 
spectra and 77.23 ppm (CDCl3) and 49.15 ppm (CD3OD) for 13C NMR spectra. ESI mass 
spectra were either recorded on a Bruker MicroToF mass spectrometer using an Agilent 
1100 HPLC to introduce samples (University of Oxford), a Micromass Quattro Ultima mass 
spectrometer using a Waters Alliance HPLC to introduce samples (University of Surrey) or a 
Waters Xevo G2-S (National Mass Spectrometry Facility, Swansea). Optical rotations were 
recorded in CDCl3 on a JASCO P-1020 polarimeter (University of Surrey), IR spectra were 
recorded on a Perkin-Elmer 2000 spectrometer (University of Surrey), and UV spectra were 
recorded using a Biochrom libraS60 in MeOH or acetonitrile in a 1 cm cell (University of 
Surrey). CD spectra were recorded using a Chirascan spectropolarimeter at room 
temperature in a 1cm cell in MeOH (University of Surrey). Reagents were purchased from 
Sigma-Aldrich Company Ltd, Gillingham, UK, SP8 4XT and used without further 
purification.
Plant Material.
The sourcing of plant material, extraction methodology and isolation of compounds from the 
bulbs of L. ovatifolia (Bak.) Jessop, L socialis (Bak.) Jessop, Rhodocodon campanulatus 
Knirsch, Mart Azoriń & Wetschnig and Rhodocodon aff. intermedius have been described 
before.24,25 Bulbs of Chinodoxa. luciliae Boiss. (Gigantea Hort), Eucomis autumnalis 
(Mill.) Chitt. and E. bicolor Baker were purchased from the Dix Export Company 
(Netherlands) in 2012 and grown to produce a flowering specimen to confirm identification. 
Voucher specimens (DAM 2012 CL, EA and EB) are retained at the University of Surrey.
Extraction and Isolation.
Dried bulbs of Chinodoxa luciliae (3.0 kg) were extracted in EtOH at room temperature for 
24 hours on a shaker. The resulting extract (119 g) was separated using gravity column 
chromatography over silica gel (Merck 9385) and solvent mixtures of 80:20 CH2Cl2:EtOAc 
(75 cm−3, 75 fractions) and 70:30 CH2Cl2:EtOAc (75 cm−3, 10 fractions). Further 
purification was necessary in some cases using PTLC (Macherey-Nagel 0.25 mm, silica gel 
60 with fluorescent indicator UV254), further column chromatography or acetylation of 
complex mixtures to obtain pure compounds. Fraction 68 yielded 15 (11 mg), fraction 70 
yielded, after further purification, 16 (2 mg) and 17 (10 mg), fraction 72 yielded 18 (17 mg) 
and after acetylation of a mixture containing 17, the monoacetate, 19 (15 mg) and diacetate 
(12 mg), 20. Fraction 74 yielded, after further purification, 21 (20 mg) and 22 (20 mg), 
Fraction 77 yielded 23 (50 mg) and fraction 80 yielded 24 (15 mg). Compounds were 
identified using 2D NMR and CD methods and by comparison against literature data as 
referenced earlier.
Chopped bulbs of E. autumnalis (4 kg) were extracted with MeOH (3 L) for 48 hours 
yielding an extract which was partitioned with CH2Cl2 (300 ml) to yield extract 1 (5.1 g) 
after solvent evaporation. Bulb material was further extracted in 1-butanol (2.5 L) for 24 
hours, yielding extract 2 (26.9 g) after solvent evaporation. Extract 1 was separated using 
gravity column chromatography over silica gel (Merck 9385) and a gradient solvent elution 
method, (40 cm−3, 63 fractions) using solvent mixtures of 50:50 hexane:CH2Cl2 (40 cm−3, 6 
fractions), 20:80 hexane:CH2Cl2 (40 cm−3, 9 fractions), 100% CH2Cl2 (40 cm−3, 4 
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fractions), 50:50 CH2Cl2:EtOAc (40 cm−3, 27 fractions), 50:50 CH2Cl2:MeOH (20 cm−3, 17 
fractions). Fraction 24 yielded, after further purification, 30 (3.5 mg), Fractions 26–7 
yielded, after further purification 31 (139.5 mg) and 32 (1.9 mg). Fractions 34–38 yielded, 
after further purification 22 (101 mg), Fractions 41–43 yielded, after further purification 33 
(15.7 mg) and 34 (7.1 mg). Fraction 45 yielded, after further purification the previously 
unreported compound 35 (37.5 mg). Red-brown oil; [α]27D −55.6 (c 0.03, CH3OH); ECD (c 
0.03, MeOH) 290 nm (−5), 230 nm (−2); IR (NaCl) νmax 3327, 3007, 2938, 2400, 2000 
1668 cm−1;1H NMR (CDCl3, 500 MHz), 13C NMR (CDCl3, 125 MHz) Table 3; HRESIMS 
m/z 347.1125 [M + H]+ (calcd for [C18H18O7 + H+, 347.1130)
Extract 2 was separated using gravity column chromatography over silica gel (Merck 9385) 
and a gradient solvent elution method, (40 cm−3, 54 fractions) using solvent mixtures of 
100% CH2Cl2 (40 cm−3, 20 fractions), 50:50 CH2Cl2:EtOAc (40 cm−3, 20 fractions), 50:50 
CH2Cl2:MeOH (20 cm−3, 14 fractions). Fractions 5–11 yielded after further purification 36 
(1.5 mg). Fractions 31–33 yielded, after further purification, 37 (1.2 mg), 38 (6.4 mg) and 39 
(1.2 mg). Compounds were identified using 2D NMR and CD methods and by comparison 
against literature data as referenced earlier.
Bulbs of E. bicolor (5 kg) were chopped and extracted EtOH (3 L) for 48 hours. The EtOH 
extract was partitioned with CH2Cl2 (300 ml) yielding Extract 3 (12.7 g) after evaporation of 
the CH2Cl2 and the remaining EtOH extract, Extract 4 (12.0 g). The bulbs were re-extracted 
in 1-butanol (2.5 L) for 24 hours, yielding Extract 5 (14.8 g) after solvent evaporation. 
Extract 3 (12.7 g) was coated onto silica, loaded into a column and separated using flash 
column chromatography using a gradient solvent elution method, (20 cm−3, 282 fractions) 
using solvent mixtures of 100% hexane (20 cm−3, 50 fractions), 50:50 hexane:CH2Cl2 (20 
cm−3, 50 fractions), 100% CH2Cl2 (20 cm−3, 50 fractions), 50:50 CH2Cl2:EtOAc (20 cm−3, 
100 fractions), 50:50 CH2Cl2:MeOH (20 cm−3, 32 fractions) Fractions 160–170 yielded 40 
(193.8 mg), Fractions 224–225 yielded 41 (321.9 mg). Extract 4 (12.0 g) was separated 
using gravity column chromatography over silica gel (Merck 9385) and a solvent mixture of 
80:20 CH2Cl2:EtOAc (100 cm−3, 9 fractions). Fraction 2 yielded 40 (60.5 mg), fractions 4–6 
yielded 41 (322.7 mg). Extract 5 (14.8 g) was separated using gravity column 
chromatography over Sephadex using a solvent mixture of 50:50 50:50 CH2Cl2:MeOH (150 
cm−3, 6 fractions). Fractions 5–6 yielded, after further purification 41 (186.7 mg) and 32 
(28.2 mg). Compounds were identified using 2D NMR and CD methods and by comparison 
against literature data as referenced earlier.
Synthesis of Compounds 42 – 50.
Preparation of (E)-5,7-dimethoxy-3-(4ʹ-methylthiobenzylidene)-4-chromanone 
(42): Under inert conditions, NaH (60% in mineral oil, 13 mmol) was added to 3,5-
dimethoxyphenol (1g, 6 mmol) in dry DMF (10 mL) at 10°C. After stirring for 60 minutes, 
3-bromopropionic acid (1.1 g, 7.2 mmol) was added and the reaction was further stirred at 
room temperature for 60 minutes. The mixture was acidified with HCl to pH 3–5, extracted 
into EtOAc and washed with brine (1 × 30 mL) and water (1 × 30 mL). The product (3-(3,5-
dimethoxyphenoxy)-propanoic acid) was used without further purification.
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Polyphosphoric acid (10g) was added to 3-(3,5-dimethoxyphenoxy)-propanoic acid and the 
resulting mixture was heated at 80°C for 2 hours. The mixture was poured into ice water and 
extracted into diethyl ether. The extract was washed with 3N NaOH (30 mL), water (50 mL) 
and dried over MgSO4. The product (3,5-dimethoxychromone) was heated at 80°C with 4-
methylthiobenzaldehyde (1:1 molar equivalent) and piperidine (4–5 drops) and the reaction 
was monitored by tlc (3:7, EtOAc:n-hexane). The mixture was diluted with water and 
extracted into EtOAc. This was washed with water (30 mL) and brine (30 mL), before 
drying over MgSO4. The resulting product was purified by flash column chromatography 
(3:7, EtOAc:n-hexane) to give (E)-5,7-dimethoxy-3-(4ʹ-methylthiobenzylidene)-4-
chromanone (42) as a yellow gum (61 mg, 3.0% overall yield).
UV (MeOH) λmax(log ε) 346 (−3.78); IR (ATR) νmax 1659, 1583,1495, 1463, 1343, 1198, 
1093, 830 cm−1; 1H NMR (CDCl3, 400 MHz) Table 4; 13C NMR (CDCl3, 100 MHz) Table 
5; HRESIMS m/z 343.0989 [M + H]+ (calcd for [C19H18O4SH + H]+, 343.0999)
Preparation of (E)-7,8-dimethoxy-3-(4ʹ-methylthiobenzylidene)-4-chromanone 
(43): Under inert conditions, NaH (60% in mineral oil, 13 mmol) was added to 2,3-
dimethoxyphenol (1g, 6 mmol) in dry DMF (10 mL) at 10°C. After stirring for 60 minutes, 
3-bromopropionic acid (1.1 g, 7.2 mmol) was added and the reaction was further stirred at 
room temperature for 60 minutes. The mixture was acidified with HCl to pH 3–5, extracted 
into EtOAc and washed with brine (1 × 30 mL) and water (1 × 30 mL). The product (3-(2,3-
dimethoxyphenoxy)-propanoic acid) was used without further purification.
Polyphosphoric acid (10g) was added to 3-(2,3-dimethoxyphenoxy)-propanoic acid (from 
above) and the resulting mixture was heated at 80°C for 2 hours. The mixture was poured 
into ice water and extracted into diethyl ether. The extract was washed with 3N NaOH (30 
mL), water (50 mL) and dried over magnesium sulphate. The product (2,3-
dimethoxychromone) was heated at 80°C with 4-methylthiobenzaldehyde (1:1 molar 
equivalent) and piperidine (4–5 drops) and the reaction was monitored by tlc (3:7, EtOAc:n-
hexane). The mixture was diluted with water and extracted into EtOAc, washed with water 
(30 mL) and brine (30 mL), before drying over MgSO4. The product was purified by flash 
column chromatography (3:7, EtOAc:n-hexane) to give (E)-7,8-dimethoxy-3-(4ʹ-
methylthiobenzylidene)-4-chromanone (43) as a yellow gum (72 mg, 3.5% overall yield).
UV (MeOH) λmax(log ε) 343 (−4.02); IR (NaCl) νmax 2921, 1665, 1580, 1572, 1493, 1425, 
1306, 1264, 1159, 820 cm−1;1H NMR (CDCl3, 400 MHz) Table 4; 13C NMR (CDCl3, 100 
MHz) Table 5; HRESIMS m/z 343.0995 [M + H]+ (calcd for [C19H18O4SH + H]+, 
343.0999)
Preparation of (E)-5,6,7-trimethoxy-3-(3ʹ-hydroxy-4ʹ-methoxybenzylidene)-4-
chromanone (44): Under inert conditions, NaH (60% in mineral oil, 13 mmol) was added 
to 3,4,5-trimethoxyphenol (1 g, 5.4 mmol) in dry DMF (10 mL) at 10°C. After stirring for 
60 minutes, 3-bromopropionic acid (1.1 g, 7.2 mmol) was added and the reaction was further 
stirred at room temperature for 60 minutes. The mixture was diluted with methanol (20 ml) 
acidified with HCl to pH 3–5, extracted into EtOAc and washed with brine (1 × 30 mL) and 
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water (1 × 30 mL). The product (3-(3,4,5-trimethoxyphenoxy)-propanoic acid) was used 
without further purification.
Polyphosphoric acid (10 g) was added to 3-(3,4,5-trimethoxyphenoxy)-propanoic acid (from 
above) and the resulting mixture was heated at 80°C for 2 hours. The mixture was poured 
into ice water and extracted into diethyl ether. The extract was washed with 3M NaOH (30 
mL), water (50 mL) and dried over MgSO4. The product (3,4,5-trimethoxychromone) was 
heated at 80°C with 3-hydroxy-4-methoxybenzaldehyde (1:1 molar equivalent) and 
piperidine (4–5 drops) and the reaction was monitored by tlc (3:7, EtOAc:n-hexane). The 
mixture was diluted with water and extracted into EtOAc, washed with water (30 mL) and 
brine (30 mL), before drying over MgSO4. The resultant product was purified by flash 
column chromatography (3:7, EtOAc:n-hexane) to give (E)-5,6,7-trimethoxy-3-(3ʹ-
hydroxy-4ʹ-methoxybenzylidene)-4-chromanone (44) as a yellow gum (0.1053 g, 5.2% 
yield).
UV (MeOH) λmax(log ε) 360 (−3.77), 348 (−3.76), IR νmax (NaCl) 3650–3590, 3376, 2936, 
2841, 1596 cm−1; 1H NMR (CDCl3, 400 MHz) Table 4; 13C NMR (CDCl3, 100 MHz) Table 
5; HRESIMS m/z 395.1096 [M + Na]+ (calcd for [C20H20O7 + Na]+, 395.1107)
Preparation of 5,6,7-trimethoxy-3(R)-(3ʹhydroxy-4ʹ-methoxybenzyl)-4-
chromanone (45): Compound 44 (34.6mg, 0.093mmol) was dissolved in deuterated 
toluene (1 mL). Iridium catalyst 1, (S)-(−)-2-[2-(diphenylphosphino)phenyl]-4-isopropyl-2-
oxazolium-(1,5)-cyclooctadiene iridium (I) tetrakis(3,5-bis(trifluoromethyl)phenyl borate 
(Scheme 2) was added (1%) and the reactor was pressurised to 5 bar with hydrogen. The 
reaction was stirred overnight at room temperature. The mixture was filtered to remove the 
catalyst and the NMR data were obtained directly in deuterated toluene (quantitative yield).
Yellow gum; [α]23D −43.8 (c 0.9, CH3OH); ECD (c 0.03, ACN) 326 nm (+1.3), 284 nm 
(−1.9) UV (MeOH) λmax (log ε) 277 (−4.20), 277 (−3.66); IR (NaCl) νmax 2936, 1674, 
1580, 1567, 1485, 1454, 1412, 1200, 1179, 1116, 822 cm−1;1H NMR (CDCl3, 400 MHz) 
Table 4; 13C NMR (CDCl3, 100 MHz) Table 5; HRESIMS m/z 397.1259 [M + Na]+ (calcd 
for [C20H22O7 + Na]+, 397.1263)
Preparation of 5,6,7-trimethoxy-3-(3ʹhydroxy-4ʹ-methoxybenzyl)-chromane 
(46): Compound 44 (50.0 mg, 0.134 mmol) was dissolved in methanol (2 mL). Pd/C (10%) 
was added, the flask was saturated with H2 (1 atmosphere) and the mixture was stirred 
overnight at room temperature. The catalyst was filtered and the solvent removed under 
reduced pressure to yield 46 (quantitative yield).
Yellow gum; UV (MeOH) λmax (log ε) 282 (−3.14); 1H NMR (CDCl3, 400 MHz) Table 4; 
13C NMR (CDCl3, 100 MHz) Table 5; HRESIMS m/z 383.1462 [M + Na]+ (calcd for 
[C20H24O6 + Na]+,383.1471)
Preparation of 5,6,7-trimethoxy-3-(3ʹhydroxy-4ʹ-methoxybenzyl)-4-
chromanone (47): Compound 44 (5.9 mg, 0.0158 mmol) was dissolved in toluene (2 mL). 
Wilkinson’s catalyst (1%) was added, the flask was saturated with H2 (1 atmosphere) and 
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the mixture was stirred overnight at room temperature. The catalyst was filtered and the 
solvent removed under reduced pressure. The mixture obtained was subject to column 
chromatography over silica gel (8:2 EtOAc:CH2Cl2) to yield 47 (2.4 mg, 40% yield). Yellow 
gum; UV (MeOH) λmax (log ε) 278 (−3.02); 1H NMR (CDCl3, 400 MHz) Table 4; 
HRESIMS m/z 397.1254 [M + Na]+ (calcd for [C20H22O7 + Na]+, 397.1263).
Preparation of (E)-5-hydroxy-6,7-trimethoxy-3-(3ʹhydroxy-4ʹ-
methoxybenzylidene)-4-chromanone (48): Compound 44 (7.9 mg, 0.021 mmol) was 
dissolved in dry CH2Cl2 (2 mL) and cooled to 0°C. TMSCl (8 equivalents) and NaI (8 
equivalents) were added and the mixture was heated to 60°C for 2 hours. The solvent was 
removed under reduced pressure and the product purified using column chromatography 
over silica gel (2:8, EtOAc: CH2Cl2) to give 5-hydroxy-6,7-trimethoxy-3-(3ʹhydroxy-4ʹ-
methoxybenzylidene)-4-chromanone (48) (4.5 mg, 60% yield).
Yellow gum; UV (MeOH) λmax (log ε) 368 (−4.03); IR (NaCl) νmax 3525, 2935, 2848, 
1643, 1579, 1511, 1455, 1359, 1272, 1202, 1106, 813, 736 cm−1; 1H NMR (CDCl3, 400 
MHz) Table 4; 13C NMR (CDCl3, 100 MHz) Table 5; HRESIMS m/z 381.0946 [M + Na]+ 
(calcd for [C19H18O7 + Na]+, 381.0950).
Preparation of (E)-5,6,7-trimethoxy-3-(4ʹ- chloro-3ʹ- hydroxybenzylidene)-4-
chromanone (49): NaH (60% in mineral oil, 13 mmol) was added to 3,4,5-
trimethoxyphenol (1 g, 5.4 mmol) in dry DMF (10 mL) at 10°C under inert conditions. After 
stirring for 60 minutes, 3-bromopropionic acid (1.1 g, 7.2 mmol) was added and the reaction 
was stirred at room temperature for a further 60 minutes. The mixture was acidified with 
HCl to pH 3–5, extracted into EtOAc and washed with brine (1 × 30 mL) and water (1 × 30 
mL). The product (3-(3,4,5-trimethoxyphenoxy)-propanoic acid) was used without further 
purification.
Polyphosphoric acid (10 g) was added to 3-(3,4,5-trimethoxyphenoxy)-propanoic acid (from 
above) and the resulting mixture was heated at 80°C for 2 hours. The mixture was poured 
into ice water and extracted with diethyl ether. The extract was washed with 3M NaOH (30 
mL), water (50 mL) and dried over magnesium sulphate. The product (3,4,5-
trimethoxychromone) was heated at 80°C with 4-chloro-3-hydroxybenzaldehyde (1:1 molar 
equivalent) and piperidine (4–5 drops) and the reaction was monitored by tlc (3:7, EtOAc:n-
hexane) and was found to be complete after 24 hours. The mixture was diluted with water 
and extracted into EtOAc, then washed with water (30 mL) and brine (30 mL), before drying 
over MgSO4. The product was purified by flash column chromatography (3:7, EtOAc:n-
hexane) to give 5,6,7-trimethoxy-3-(4ʹ-chloro-3ʹ- hydroxybenzylidene)-4-chromanone (49) 
as a yellow powder (155 mg, 7.8% yield).
UV (MeOH) λmax (log ε) 295 (−3.94), 352 (−3.77); IR (NaCl) νmax 3328, 2939, 1661, 
1650, 1488, 1470, 1415, 1391, 1258, 1201, 1171, 1100, 818 cm−1; 1H NMR (CDCl3, 400 
MHz) Table 4; 13C NMR (CDCl3, 100 MHz) Table 5; HRESIMS m/z 377.0786 [M + H]+ 
[calcd for (C19H17O6Cl + H)+,377.0792].
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Preparation of (E)-3-(3,4-dimethoxylphenyl)-1-(4-ethoxy-2-hydroxy-3-methyl-
phenyl)prop-2-en-1-one (50): 4-Ethoxy-2-hydroxy-3-methyl acetophenone (0.1 g, 0.51 
mmol) was added to 3,4-dimethoxybenzaldehyde (0.85 g, 0.51 mmol) and 10% NaOH (1 
mL) in methanol (5 ml) and stirred at room temperature for 2 hours. Upon standing, (E)-3-
(3,4-dimethoxylphenyl)-1-(4-ethoxy-2-hydroxy-3-methyl-phenyl)prop-2-en-1-one (50) 
precipitated out as a yellow powder and was isolated by vacuum filtration (25.9 mg, 15% 
yield).
UV (MeOH) λmax (log ε) 368 (−4.62); IR (ATR) νmax 1650, 1570,1550, 1499, 1419, 1364, 
1265, 1221, 1080, 847 cm−1;1H NMR (CDCl3, 400 MHz) Table 4; 13C NMR (CDCl3, 100 
MHz) Table 5; HRESIMS m/z 343.1545 [M + H]+ [calcd for (C20H22O5+ H)+, 343.1545].
Biological Methods
Materials—Human retinal microvascular endothelial cells (HRECs; Cell Systems, Seattle, 
WA) and human umbilical vein endothelial cells (HUVECs; Lonza, Walkersville, MD), were 
used between passage 5 and 8. Endothelial Growth Medium (EGM-2) was prepared by 
mixing the contents of an EGM-2 “Bullet Kit” (Cat no. CC-4147) with Endothelial Basal 
Medium (EBM) (Cat no. CC-3156) (Lonza). 92–1 uveal melanoma cells (a kind gift of Dr. 
Martine Jager, University of Leiden) were grown in RPMI medium containing 10% FBS and 
1% penicillin-streptomycin (pen-strep). Y-79 retinoblastoma cells (a kind gift of Dr. Brenda 
L. Gallie, Ontario Cancer Institute) were grown in RB medium (IMDM + 10% FBS + 55 
μM β-mercaptoethanol + 10 μg/mL Insulin + 1% pen-strep). ARPE-19 retinal pigment 
epithelial cells (ATCC, Manassas, VA) were grown in DMEM containing 10% FBS and 1% 
pen-strep. AlamarBlue reagent (product code BUF012B) was from AbD Serotec (Raleigh, 
NC). Matrigel matrix basement membrane (Cat no.354234) was purchased from Corning 
(Corning, NY)
Cell proliferation assay: The antiproliferative activities of different compounds were 
monitored by an alamarBlue based fluorescence assay as described previously.43 Five cell 
types were used: the target endothelial cell type (HRECs), a non-target endothelial cell type 
(HUVECs), a non-target normal retinal pigment epithelial cell line (ARPE-19), a non-target 
uveal melanoma cell line (92–1), and a non-target retinoblastoma cell line (Y79). Briefly, 
2,500 cells in 100 μL growth medium were incubated in 96-well clear bottom black plates 
for 24 hours at 37°C, 5% CO2, different concentrations of each test compound were then 
added (range: 0.5 nM to 500 μM) followed by 44 hours incubation. 11.1 μL of alamarBlue 
reagent was then added and after 4 hours, fluorescence readings were taken on a Synergy H1 
plate reader (Biotek, Winooski, VT) with excitation and emission wavelengths of 560 nm 
and 590 nm respectively. GraphPad Prism software (v. 7.0) was used for data analysis. 
Compounds that reduced cell number by 50% or more at the highest concentration tested 
(relative to DMSO control) were reported as having a GI50 < 100μM.
In vitro tube formation assay: A Matrigel based tube formation assay was performed to 
monitor the ability of HRECs to form tube-like structures in the presence of different 
concentrations of 13, 27, 28, 45, 46, 48 and 50, as described previously.20 Briefly, 15,000 
cells in 100 μL EGM-2 medium were incubated in the absence (DMSO treated) and 
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presence of different concentrations of each compound in 96-well clear plates coated with 
50 μL of Matrigel basement membrane. Known antiangiogenic homoisoflavonoid 
SH-1103721 was a positive control. After 8 hours, the images were recorded using an EVOS 
FL microscope (AMG, Mill Creek, WA) and the tube length was measured using 
Angiogenesis Analyzer macros in ImageJ (http://image.bio.methods.free.fr/ImageJ/?
Angiogenesis-Analyzer-for-ImageJ).
Statistical analysis: The data obtained from tube formation experiments were analyzed by 
one-way ANOVA with Dunnett’s post hoc tests for comparisons between compounds’ 
treatments and control. All analyses were performed using GraphPad Prism software (v.7.0). 
A p value of <0.05 was considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
HMBC correlations (H → C) for compound 35.
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Figure 2. 
Homoisoflavonoids block the proliferation of HRECs. Dose-response curves for 
representative active compounds’ effects on proliferation of the indicated cell types as 
assessed by alamarBlue fluorescence. Mean ± SEM, n=3–6 wells.
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Figure 3. 
Potent natural-source homoisoflavonoids significantly block the ability of HRECs to form 
tube-like structures. Top, Representative images of the tube formation of HRECs on 
Matrigel at the highest concentrations of each compound tested plus DMSO control, scale 
bars = 250 μm. Bottom, Quantification of the extent of tube formation was measured as 
tubule length of HRECs treated with compounds compared to DMSO control. Mean ± SEM, 
n=3–6 wells. Representative results from duplicate experiments. *P<0.05, ***P<0.001 
compared to DMSO control (One-way ANOVA with Dunnett’s post-hoc tests).
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Figure 4. 
Potent synthetic homoisoflavonoids significantly block the ability of HRECs to form tube-
like structures. Top, Representative images of the tube formation of HRECs on Matrigel at 
the highest concentrations of each compound tested plus DMSO control, scale bars = 500 
μm. Bottom, Quantification of the extent of tube formation was measured as tubule length of 
HRECs treated with each compound compared to DMSO control. SH-11037 is a positive 
control. Mean ± SEM, n=6 wells. Representative results from duplicate experiments. 
*P<0.05, ***P<0.001 compared to DMSO control (One-way ANOVA with Dunnett’s post-
hoc tests).
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Figure 5. 
Highly potent synthetic homoisoflavonoid 46 significantly blocks the ability of HRECs to 
form tube-like structures. Top, Representative images of the tube formation of HRECs on 
Matrigel, scale bars = 500 μm. Bottom, Quantification of the extent of tube formation was 
measured as tubule length of HRECs treated with compound compared to DMSO control. 
Mean ± SEM, n=6 wells. Representative results from duplicate experiments. ***P<0.001 
compared to DMSO control (One-way ANOVA with Dunnett’s post-hoc tests).
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Scheme 1. 
General scheme for synthesis of 3-benzylidene homoisoflavonoids.
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Scheme 2. 
Reactions of Compound 44. (Iridium catalyst = (S)-(−)-2-[2-(diphenylphosphino)phenyl]-4-
isopropyl-2-oxazolium-(1,5)-cyclooctadiene iridium (I) tetrakis(3,5-
bis(trifluoromethyl)phenyl borate).
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